NASDAQ$MRSN
Mersana Therapeutics Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Mersana reported its Q3 2024 financial results and provided a business update.
Mersana Therapeutics reported its Q3 2024 financial results, highlighting the advancement of XMT-1660 and XMT-2056 clinical trials, progress in collaborations, and maintenance of a strong balance sheet. The company is preparing to present initial XMT-1660 clinical data and initiate the expansion portion of its trial.
- Advanced the dose escalation portions of Phase 1 clinical trials of XMT-1660 and XMT-2056.
- Made further progress in collaborations with Johnson & Johnson and Merck KGaA, Darmstadt, Germany.
- Preparing to present initial XMT-1660 clinical data later this year and initiate the expansion portion of the trial in patients with TNBC.
- Achieved an $8 million development milestone under the Johnson & Johnson collaboration and a $1 million development milestone under the Merck KGaA, Darmstadt, Germany collaboration.
Headline financials
Revenue & EPS history
Mersana · Revenue · Quarterly
$12.6M
Forward guidance
Mersana plans to share initial safety, tolerability, efficacy and biomarker data from its Phase 1 dose escalation and backfill cohorts at a company event and to initiate the expansion portion of the trial in patients with TNBC who have previously been treated with at least one topo-1 ADC.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q3 2024
+1.4%
Avg return
Earnings day
+2.5%
Avg return
5 days after
+1.3%
Avg return
30 days after
47%
17 / 36 earnings
Positive
+38.9%
Q2 2022
Best reaction
-20.3%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | +2.4% | +0.8% | +3.0% | |
| Q2 2025 | +11.6% | +22.3% | +18.6% | |
| Q1 2025 | -18.5% | -0.2% | -3.6% | |
| Q4 2024 | -8.3% | +3.6% | -36.7% | |
| Q3 2024 | +14.5% | -3.7% | -1.8% | |
| Q2 2024 | -13.4% | -7.2% | +25.2% | |
| Q1 2024 | -20.3% | -23.8% | -37.4% | |
| Q4 2023 | +27.4% | +33.8% | +4.8% | |
| Q3 2023 | -6.5% | -12.9% | +46.8% | |
| Q2 2023 | +0.0% | +4.2% | +6.7% | |
| Q1 2023 | +8.9% | +8.2% | +16.4% | |
| Q4 2022 | +7.0% | +4.4% | -26.3% | |
| Q3 2022 | -11.0% | — | — | |
| Q2 2022 | +38.9% | — | — | |
| Q1 2022 | -11.2% | — | — | |
| Q4 2021 | +14.4% | — | — | |
| Q3 2021 | -1.1% | — | — | |
| Q2 2021 | -2.1% | — | — | |
| Q1 2021 | -5.3% | — | — | |
| Q4 2020 | +7.7% | — | — | |
| Q3 2020 | -4.2% | — | — | |
| Q2 2020 | -1.9% | — | — | |
| Q1 2020 | -3.1% | — | — | |
| Q4 2019 | +3.5% | — | — | |
| Q3 2019 | +7.0% | — | — | |
| Q2 2019 | +2.3% | — | — | |
| Q1 2019 | +14.3% | — | — | |
| Q4 2018 | +4.0% | — | — | |
| Q3 2018 | +7.5% | — | — | |
| Q2 2018 | +0.0% | — | — | |
| Q1 2018 | -3.7% | — | — | |
| Q1 2016 | -8.9% | — | — | |
| Q3 2016 | -4.5% | — | — | |
| Q3 2017 | -5.1% | — | — | |
| Q4 2016 | +3.9% | — | — | |
| Q2 2016 | +3.9% | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro